Intra-Cellular Therapies (ITCI) has been under a strong bear grip, hence the stock is down -1.76% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.12% in the past 1 week. The stock has risen by 1.09% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.38% in the past 4 weeks.
Intra-Cellular Therapies, Inc. is up 15.61% in the last 3-month period. Year-to-Date the stock performance stands at -24.28%. The stock has recorded a 20-day Moving Average of 1.14% and the 50-Day Moving Average is 2.34%.
Intra-Cellular Therapies (NASDAQ:ITCI): The stock opened at $40.71 on Friday but the bulls could not build on the opening and the stock topped out at $41.05 for the day. The stock traded down to $40.49 during the day, due to lack of any buying support eventually closed down at $40.73 with a loss of -0.56% for the day. The stock had closed at $40.96 on the previous day. The total traded volume was 304,897 shares.
Also, Piper Jaffray initiates coverage on Intra-Cellular Therapies (NASDAQ:ITCI). The current rating of the shares is Overweight, according to the research report released by the firm. The brokerage firm announces the price target at $57 per share. The rating by the firm was issued on June 2, 2016.
ITI Inc. is a United States-based company. The Company is a subsidiary of Intra-Cellular Therapies Inc.